Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Oncology Update

Oncology Update

Michael Smart
ONF 2012, 39(1), 109-110 DOI: 10.1188/12.ONF.109-110

Cetuximab (Erbitux®) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard chemotherapy (a platinum plus 5-fluorouracil) for first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or